← Eichor
Condition: Liver Cancer Locally Advanced Or Metastatic Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Liver Cancer Locally Advanced Or Metastatic

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves T
Phase 1 · 11 location(s) · AbbVie · NCT06487559Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Tango Therapeutics, Inc. · NCT05732831FDG PET-CT in Advanced Breast Cancer
Phase N/A · 1 location(s) · Samsung Medical Center · NCT07173868Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 · 10 location(s) · Nammi Therapeutics Inc · NCT06582017A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solut
Phase 2/Phase 3 · 37 location(s) · AbbVie · NCT06109272A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectab
Phase 1/Phase 2 · 21 location(s) · Tvardi Therapeutics, Incorporated · NCT05440708FOG-001 in Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 33 location(s) · Parabilis Medicines, Inc. · NCT05919264Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen
Phase 1/Phase 2 · 49 location(s) · Pfizer · NCT07227012Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or W
Phase 2 · 1 location(s) · Shanghai Henlius Biotech · NCT06349980A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Phase 1 · 6 location(s) · Angiex, Inc. · NCT06440005Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metast
Phase 1 · 2 location(s) · Aadi Bioscience, Inc. · NCT05661461Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Phase 2 · 12 location(s) · Replimune, Inc. · NCT05733598Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410676A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to
Phase 2 · 1 location(s) · Shanghai Henlius Biotech · NCT06742892Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)
Phase 2 · 1 location(s) · Niek Wijnen · NCT07312292A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Phase 1 · 1 location(s) · Nanjing Sanhome Pharmaceutical, Co., Ltd. · NCT07390838Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metast
Phase 2 · 16 location(s) · Academic and Community Cancer Research United · NCT05168163
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.